Improvement of endothelial function by pitavastatin: a meta-analysis

Niki Katsiki, Željko Reiner, Eugenia Tedeschi Reiner, Khalid Al-Rasadi, Matteo Pirro, Dimitri P. Mikhailidis, Amirhossein Sahebkar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number3
DOIs
Publication statusPublished - Feb 11 2018

Fingerprint

Meta-Analysis
Dilatation
Clinical Trials
Confidence Intervals
HDL Lipoproteins
Dyslipidemias
PubMed
LDL Cholesterol
HDL Cholesterol
pitavastatin
Databases
Therapeutics

Keywords

  • atherosclerosis
  • endothelial function
  • flow-mediated dilation
  • meta-analysis
  • Pitavastatin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Katsiki, N., Reiner, Ž., Tedeschi Reiner, E., Al-Rasadi, K., Pirro, M., Mikhailidis, D. P., & Sahebkar, A. (2018). Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opinion on Pharmacotherapy, 19(3), 279-286. https://doi.org/10.1080/14656566.2018.1428560

Improvement of endothelial function by pitavastatin : a meta-analysis. / Katsiki, Niki; Reiner, Željko; Tedeschi Reiner, Eugenia; Al-Rasadi, Khalid; Pirro, Matteo; Mikhailidis, Dimitri P.; Sahebkar, Amirhossein.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 3, 11.02.2018, p. 279-286.

Research output: Contribution to journalArticle

Katsiki, N, Reiner, Ž, Tedeschi Reiner, E, Al-Rasadi, K, Pirro, M, Mikhailidis, DP & Sahebkar, A 2018, 'Improvement of endothelial function by pitavastatin: a meta-analysis', Expert Opinion on Pharmacotherapy, vol. 19, no. 3, pp. 279-286. https://doi.org/10.1080/14656566.2018.1428560
Katsiki, Niki ; Reiner, Željko ; Tedeschi Reiner, Eugenia ; Al-Rasadi, Khalid ; Pirro, Matteo ; Mikhailidis, Dimitri P. ; Sahebkar, Amirhossein. / Improvement of endothelial function by pitavastatin : a meta-analysis. In: Expert Opinion on Pharmacotherapy. 2018 ; Vol. 19, No. 3. pp. 279-286.
@article{f1ecab340ea040ed9f20cb9c01115d6e,
title = "Improvement of endothelial function by pitavastatin: a meta-analysis",
abstract = "Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95{\%} confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45{\%}, 95{\%} CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.",
keywords = "atherosclerosis, endothelial function, flow-mediated dilation, meta-analysis, Pitavastatin",
author = "Niki Katsiki and Željko Reiner and {Tedeschi Reiner}, Eugenia and Khalid Al-Rasadi and Matteo Pirro and Mikhailidis, {Dimitri P.} and Amirhossein Sahebkar",
year = "2018",
month = "2",
day = "11",
doi = "10.1080/14656566.2018.1428560",
language = "English",
volume = "19",
pages = "279--286",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Improvement of endothelial function by pitavastatin

T2 - a meta-analysis

AU - Katsiki, Niki

AU - Reiner, Željko

AU - Tedeschi Reiner, Eugenia

AU - Al-Rasadi, Khalid

AU - Pirro, Matteo

AU - Mikhailidis, Dimitri P.

AU - Sahebkar, Amirhossein

PY - 2018/2/11

Y1 - 2018/2/11

N2 - Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.

AB - Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.

KW - atherosclerosis

KW - endothelial function

KW - flow-mediated dilation

KW - meta-analysis

KW - Pitavastatin

UR - http://www.scopus.com/inward/record.url?scp=85041111157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041111157&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1428560

DO - 10.1080/14656566.2018.1428560

M3 - Article

C2 - 29334477

AN - SCOPUS:85041111157

VL - 19

SP - 279

EP - 286

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -